ZYBERNO
Stock Report
Updated Sep 2, 2026

Silence Therapeutics plc (SLNCF)

Healthcare • OTC

$4.00

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
18.0/100
POOR BUSINESS
Silence Therapeutics plc (SLNCF) scores 18/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-106.9%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.01x)
Operating Margin (Operational Efficiency):CRITICAL (-16,380.6%)
Return on Capital (Capital Efficiency):CRITICAL (-149.1%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Silence Therapeutics plc (SLNCF) stock report — Zyberno Score 18/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, SLNCF generated -$65.62M in Owner Earnings. Capital was deployed as follows: $51.00K invested in capital expenditures. Reinvestment rate: 0.5%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:4.00
Market Cap:$566.84M

Valuation Multiples (3)

P/B Ratio:14.73x
P/S Ratio:1,359.33x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$494.90M

Price Action & Momentum (1)

% of 52-Week High:66.8%
B. Profitability Assessment

Return Metrics (5)

ROA:-48.0%
Reinvestment Rate:0.5%
Fundamental Growth Rate (g):-0.8%

Margin Analysis (3)

Operating Margin Ttm:-16,380.6%
Net Margin Ttm:-14,377.2%
Ebitda Margin:-16,306.0%

TTM Performance (3)

Gross Margin Ttm:61.4%
Operating Margin Ttm:-16,380.6%
Net Margin Ttm:-14,377.2%

Yield Metrics (2)

Earnings Yield:-$7.35
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-50.0%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:7.42x
Quick Ratio:7.42x
Cash Ratio:5.67x

Leverage Analysis (3)

Debt To Equity Ttm:0.01x
Debt-to-Equity Ratio:0.01x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:81,567,000.00
Cash And Cash Equivalents:72,054,000.00
Long Term Debt:$9.00K
Net Debt:-$71.94M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $417.00K
Linear Growth: -50.0%
📊 Click to view full SLNCF Revenue analysis & methodology →
Cost Of Revenue Ttm:$87.00K

Profitability Breakdown (2)

Gross profit TTM: $256.00K
Linear Growth: -50.0%
📊 Click to view full SLNCF Gross Profit analysis & methodology →
-$68.31M

Bottom Line Performance (3)

-$59.95M
Income Before Tax:-$59.95M
Ebitda Ttm:-67,996,000.00

Operating Expenses (5)

Operating Expenses:0.00
R And D Expense:47,563,000.00
Sga Expense:21,272,000.00
Income Tax Expense:$2.00K
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:-16,306.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$106.41M
Current Assets:$94.28M
Ppe Net:1,325,000.00
Goodwill:10,325,000.00
Intangible Assets:$237.00K

Liability Structure (4)

Total Liabilities:67,941,000.00
Current Liabilities:12,714,000.00
Long Term Debt:$9.00K
Short Term Debt:$103.00K

Equity & Capital (3)

Equity:$38.47M
Retained Earnings:-$589.63M
Common Stock:10,292,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:0.00

Special Items (2)

Contract Liabilities:55,218,000.00
Stock Based Compensation:2,447,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$65.57M-$65.62M

Investment Activities (2)

Investing Cash Flow:$10.00M
Capital Expenditures Ttm:51,000.00

Financing Activities (3)

Financing Cash Flow:$0.00
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:311,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.44
-$0.44
Earnings Per Share Ttm:-$0.42

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.00
Operating Cash Flow Per Share:-$0.44

Book Value & Capital (2)

Book Value Per Share:$0.27
Cash Per Share:0.51

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.00x
Working Capital Turnover Ttm:0.01x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$65.62M

Damodaran Growth Analysis (2)

Reinvestment Rate:0.5%
Fundamental Growth Rate (g):-0.8%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-50.0%

Other Growth Rates (2)

Gross Profit Growth Rate (Linear):-50.0%
Book Value Growth Rate (Linear):-50.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:SLNCF
Company Name:Silence Therapeutics plc
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:OTC
Country:Unknown

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:141.71M
Shares Outstanding Basic:141.71M
Shares Outstanding Diluted:141.71M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-02 04:08:35 UTC
Data Timestamp:2026-08-24T09:08:51.382449
Scroll to Top